The development of prostate
carcinoma is associated with alterations in
fatty acid metabolism. α-Methylacyl-
CoA racemase (AMACR) is a peroxisomal and mitochondrial
enzyme that catalyses interconversion between the (S)/(R)-isomers of a range of α-methylacyl-
CoA thioesters. AMACR is involved in the β-oxidation of the dietary branched-chain
fatty acids and
bile acid intermediates. It is highly expressed in prostate (more than 95 %), colon (92 %), and breast
cancers (44 %) but not in the respective normal or hyperplastic tissues. Thus, targeting of AMACR could be a new strategy for molecular imaging and
therapy of prostate and some other
cancers. Unlabeled 2-methylenacyl-CoA thioesters (12 a-c) were designed as AMACR binding
ligands. The thioesters were tested for their ability to inhibit the AMACR-mediated epimerization of (25R)-THC-CoA and were found to be strong AMACR inhibitors. Radioiodinated (E)-(131) I-13-iodo-2-methylentridec-12-enoic
acid ((131) I-7 c) demonstrated preferential retention in AMACR-positive prostate
tumor cells (LNCaP, LNCaP C4-2wt and DU145) compared with both AMACR-knockout LNCaP C4-2 AMACR-
siRNA and benign BPH1 prostate cell lines. A significant
protein-bound radioactive fraction with main bands at 47 (sum of molecular weights of AMACR plus 12 c), 70, and 75 kDa was detected in LNCaP C4-2 wt cells. In contrast, only negligible amounts of
protein-bound radioactivity were found in LNCaP C4-2 AMACR-
siRNA cells.